Protagonist Therapeutics Inc

PTGX

Company Profile

  • Business description

    Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

  • Contact

    7707 Gateway Boulevard
    Suite 140
    NewarkCA94560
    USA

    T: +1 510 474-0170

    E: [email protected]

    https://www.protagonist-inc.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    124

Stocks News & Analysis

stocks

10 best US dividend aristocrats to buy now—including a surprise outperformer

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks

Leading ASX players in this field look materially overvalued

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,970.5044.90-0.50%
CAC 407,861.964.600.06%
DAX 4024,262.2244.850.19%
Dow JONES (US)44,461.28171.71-0.38%
FTSE 1009,136.940.620.01%
HKSE25,176.93347.52-1.36%
NASDAQ21,129.6731.380.15%
Nikkei 22540,814.94160.240.39%
NZX 50 Index12,850.185.79-0.05%
S&P 5006,362.907.96-0.12%
S&P/ASX 2008,713.4043.00-0.49%
SSE Composite Index3,615.726.010.17%

Market Movers